Lianhuan Pharmaceutical: Subsidiary receives approval notice for supplementary drug application

2026-03-28 11:34:55

Lianhuan Pharmaceutical announced that its holding subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., recently received the approval notice for the supplementary application of Nicorandil tablets issued by the National Medical Products Administration. Nicorandil tablets are used for the treatment of angina pectoris. As of the date of this announcement, the estimated sales revenue of this drug in domestic sample hospitals for the year 2024 is approximately 635 million yuan, and Changle Pharmaceutical’s research and development investment for this drug is approximately 7.2 million yuan (unaudited). The production license obtained this time is the first production license for Changle Pharmaceutical in 2026.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes